The role of somatostatin analogues in treatment of TSH secreting pituitary adenomas

Zgliczyński, Wojciech; Zdunowski, Piotr; Czajka-Oraniec, Izabella; Jeske, Wojciech; Zieliński, Grzegorz

doi:10.1186/1756-6614-6-s2-a64

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiotherapy (conventional fractional radiotherapy or radiosurgery) may also be indicated in the treatment of TSHoma; however, the benign character of the condition, the potential side effects of radiation in particular hypopituitarism, and the long delay between radiation and efficacy will make its use less frequent, especially when medical therapies provide good control of the disease as we will see below [29]. Somatostatin analogs (SA) are the best choice of medical alternative treatment; they restore normal thyroid function in about 95% and shrink the size of TSHoma in up to 50% of patients [30][31][32]. Resistance to SA in our case is most likely related to nonexpression of somatostatin receptors.…”

Section: Sitshmentioning

confidence: 99%

Simultaneous Coexistence of Thyrotropin-Prolactin-Secreting Adenoma and Papillary Thyroid Carcinoma

Safi

Benabdelfedil

Derrou

et al. 2021

Case Reports in Endocrinology

View full text Add to dashboard Cite

Background. The thyrotropin-secreting adenomas are very rare and even more rare when they simultaneously coexist with thyroid carcinoma. So far, only sixteen cases have been reported in the literature. Here, we present a unique case of successful management of a concurrent case of thyrotropin-prolactinoma with papillary thyroid carcinoma. Case Presentation. A 50-year-old Moroccan woman underwent a total thyroidectomy and complementary totalization by iratherapy for papillary thyroid carcinoma, who presented persistence of an inappropriate secretion of the thyroid-stimulating hormone (TSH > 4 mUI/L) despite of levothyroxine suppressive therapy (300 μg/d). After eliminating noncompliance, interfering medicines, and thyroid malabsorption, a pituitary adenoma (12 mm) was documented at magnetic resonance imaging. The patient has had transsphenoidal pituitary adenomectomy with histology confirming a thyrotropin-prolactin-secreting adenoma. After surgery and lanreotide treatment failures, we noted a complete response (TSH < 0.5) with cabergoline treatment (3 mg/week). Conclusion. The unusual association of thyroid adenocarcinoma and TSHoma enriches the hypothesis of a potential link between thyrotropic hypersecretion and thyroid carcinogenesis. Our case also illustrates the difficulty of monitoring thyroid carcinoma in nonremission of a TSHoma.

show abstract